Mycobacteria Identification and M. Tuberculosis Drug Resistance Detection Array Kit

Identify 17 mycobacterial species  frequently isolated in clinical laboratories

CapitalBio Mycobacteria Identification Array Kit provides a novel method to identify 17 mycobacterial species that are most frequently isolated in clinical laboratories. CapitalBio M. tuberculosis Drug Resistance Detection Array Kit is used for the detection of 16 of the most frequently discovered site mutations in four genes which are strongly implicated in resistance to the three most important (first-line) anti-tuberculosis drugs, rifampicin, isoniazid and streptomycin. With the combination of special primer design, strictly controlled multiplex PCR procedure, standard array hybridization process and automatic analysis software, the kit offers a rigorous high throughput method to aid making personalized therapy recommendations.
In 2005, there were an estimated 8.8 million new Tuberculosis (TB) cases, 7.4 million in Asia and sub-Saharan Africa. Some 1.6 million people died of TB, including 195,000 patients infected with HIV. Early diagnosis and drug resistance detection helps increase the TB cure rate.

Key Features
★ Simple and versatile sample preparation: DNA extraction can be performed either from isolated strain cultures or directly from clinical sputum samples
★ High sensitivity: our assay sensitivity is much higher than other traditional methods, because of its specially designed primer pairs and multiplex PCR procedures
★ High accuracy: multiple data control design and optimized conditions for multiplex PCR amplification ensure the rigorous accuracy of the assay
★ Fast analysis: the entire detection time required is less than 6 hours. This is remarkably shorter than traditional biochemical methods which require at least two weeks
★ High consistency: strict step-by-step quality controls are used throughout the whole process, ensuring precise and reproducible results

Ordering Information